Scarica l'app Stockscreener
7.33
0.14%
-0.010
Dopo l'orario di chiusura:
7.41
0.08
+1.09%
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Can Vanda Pharmaceuticals Inc. (VM4) stock surprise markets with earningsJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock affected by interest rate hikes2025 Historical Comparison & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock positioned well for digital economyEarnings Recap Report & Reliable Entry Point Alerts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. (VM4) stock good for long term investingWeekly Risk Report & Low Drawdown Trading Techniques - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application - GuruFocus
FDA rejects Vanda's jet lag drug application days after approving motion sickness drug - The Business Journals
How Vanda Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Sector Moves & Low Risk High Win Rate Picks - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection - GuruFocus
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision - GuruFocus
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application - TipRanks
Vanda Pharmaceuticals stock falls after FDA rejects jet lag treatment application - Investing.com UK
Vanda Pharmaceuticals Inc Receives FDA Decision on HETLIOZ® sNDA for Jet Lag - TradingView — Track All Markets
FDA pushes back on new drug that aimed to ease jet lag for travelers - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Evaluating a 59.54% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Vanda Pharma says FDA is in violation of FDCA regarding its Hetlioz sNDA - The Pharma Letter
Will Vanda Pharmaceuticals Inc. stock outperform tech sector in 2025Candlestick Trading Patterns & High Yield Portfolio Picks - ulpravda.ru
Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application - Stocktwits
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat
FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance
VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn
VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus
Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1 - MSN
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley - Yahoo Finance
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus (NASDAQ:VNDA) - Seeking Alpha
After 40 Years, USFDA Approves Vanda Pharma's Motion Sickness Drug Nereus - Medical Dialogues
VNDA obtains FDA nod for motion sickness drug, stock gains - MSN
Vanda wins FDA approval for NEREUS motion sickness drug - MSN
Jefferies Initiates Vanda Pharmaceuticals(VNDA.US) With Hold Rating, Announces Target Price $7.5 - 富途牛牛
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters
D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals
What's Going On With Vanda Pharmaceuticals Stock Wednesday? - Benzinga
Vanda Pharmaceuticals: Could Now Be A Good Time To Invest? - StocksToTrade
Vanda surges 28% after FDA approval - breakingthenews.net
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛
B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus
Vanda Pharmaceuticals price target raised to $14 from $11 at B Riley - MSN
Vanda Pharmaceuticals Inc. (VNDA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week HighHere's What Happened - MarketBeat
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects - GuruFocus
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy - GuruFocus
Vanda Pharmaceuticals Stock Jumps After FDA Approves Motion Sickness Drug - Barron's
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval - Barron's
Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies - TipRanks
Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying - GuruFocus
Vanda Pharmaceuticals Stock Rockets: Time to Ride the Wave? - timothysykes.com
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus - Pharmaceutical Technology
Vanda Pharmaceuticals stock soars after FDA approval of motion sickness drug - Investing.com Nigeria
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):